• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

failed trials

Brain scan neuroscience
Biotech

Priavoid’s Alzheimer’s pill fails to prove efficacy in ph. 2

Priavoid’s pill for Alzheimer's failed to prove its worth in phase 2, although the biotech pointed to encouraging signs in the longer-term data.
James Waldron Nov 18, 2026 4:21am
merck

Merck axes $2.7B BTK inhibitor program after seeing ph. 3 data

Nov 18, 2026 3:11am
failure crash no fail rocket cancelled end

Aclaris drops TSLP program after failing ph. 2 eczema test

Nov 16, 2026 8:20am
Goal disorientation and lack of vision

Zura scraps hidradenitis suppurativa program after phase 2 miss

Nov 9, 2026 9:21am
NVS

AHA: Novartis’ Lp(a) drug shows zero benefit

Nov 7, 2026 9:50am
Servier

Servier’s $1.6B muscular dystrophy bet fails pivotal test

Nov 4, 2026 3:06am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings